Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis

GlobeNewswire April 12, 2022

Pfizer Names David M. Denton Chief Financial Officer

Business Wire April 11, 2022

Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates

Business Wire April 7, 2022

Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential

PR Newswire March 29, 2022

 Pfizer and BioNTech Receive Expanded U.S. Emergency Use Authorization for an Additional COVID-19 Vaccine Booster in Individuals Aged 50 Years and Older

Business Wire March 29, 2022

Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential

Business Wire March 29, 2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults

Business Wire March 24, 2022

Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients

Business Wire March 23, 2022

Pfizer Invites Public to View and Listen to Webcast of May 3 Conference Call with Analysts

Business Wire March 22, 2022

Pfizer to Supply UNICEF up to 4 Million Treatment Courses of Novel COVID-19 Oral Treatment for Low- and Middle-Income Countries

Business Wire March 22, 2022

IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors

PR Newswire March 14, 2022

Pfizer Completes Acquisition of Arena Pharmaceuticals

Business Wire March 11, 2022

Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants

Business Wire March 9, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire March 8, 2022

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

GlobeNewswire March 8, 2022

Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus (RSV) Vaccine Candidate for the Prevention of RSV in Infants from Birth up to Six Months of Age by Active Immunization of Pregnant Women

Business Wire March 2, 2022

Phase 3 CLOVER Trial for Pfizer's Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints

Business Wire March 1, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Business Wire February 28, 2022

Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment

PR Newswire February 25, 2022

Pfizer Invites Public to View and Listen to Webcast of Pfizer Keynote Presentation at Healthcare Conference

Business Wire February 22, 2022